Since its inception 17 years ago, the BIO Investor Forum has become the premier event where biotech innovators can find investors and strategic partners to advance their company to the next stage in their business life cycle. Over the past two days, more than 340 private equity and public investors from around the world, with increased representation from the Asia markets, have sought out and met with the myriad of biotechs ready to spotlight their promising developments.
Attendance set a new record, with delegates from 27 countries, giving the event a distinctly international flavor. Many were drawn to the conference’s expertly led panel sessions and the increased interest from the investment community, especially in rapidly evolving areas of scientific and medical discoveries like gene therapy, cell therapy, genome editing and other innovative technologies. More than 3,150 BIO One-on-One Partnering™ meetings took place during the two-day event, an increase over last year.
The event welcomed industry thought leaders discussing the latest in cancer treatments, gene therapies, CNS drug development, molecular diagnostics as well as business themes including board diversity, CFIUS, the IPO market, policy outlook, and investor engagement best practices. Other sessions looked at the ever-increasing digital space including applying artificial intelligence to improve therapy development.
BIO also launched ‘On the Road with Good Day BIO’, a series of #BIF19 highlights as well as interviews with participating speakers and industry opinion leaders reflecting an optimism for fueling investment in biotech start-ups. Click here to view the videos.